NCT03502200View on ClinicalTrials.gov

Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures

NACompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Smoking, Cigarette
Interventions
DEVICE

JUUL

Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.

OTHER

Treatment As Usual

Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT03502200 - Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures | Biotech Hunter | Biotech Hunter